ABSTRACT
Objectives To assess the prevalence of long COVID among people with multiple sclerosis (MS) and its predictors, including their pre-COVID-19 functional status.
Design Community-based prospective and longitudinal cohort study
Setting The United Kingdom (UK) MS Register (UKMSR) COVID-19 study
Participants A national cohort of people with MS and COVID-19
Main outcome measures Participants used the online questionnaire-based platform of the UKMSR to update their COVID-19 symptoms, recovery status, and duration of symptoms for those who had fully recovered. Questionnaires were date-stamped for estimation of COVID-19 symptom duration for those who had not recovered at their last follow-up. The UKMSR holds demographic and up-to-date clinical data on participants as well as their web-based Expanded Disability Status Scale (a measure of physical disability in MS) and Hospital Anxiety and Depression Scale scores. The association between these factors and recovery from COVID-19 was assessed using multivariable Cox regression analysis.
Results Out of 7,977 people with MS who participated in the UKMSR COVID-19 study, 599 had COVID-19 and updated their recovery status prospectively. At least 181 participants (31.1%) had long-standing COVID-19 symptoms for ≥4 weeks and 76 (13.1 %) for ≥12 weeks. Participants with higher levels of pre-COVID-19 physical disability, participants with anxiety and/or depression prior to COVID-19 onset, and women were less likely to report recovery from COVID-19.
Conclusions Long COVID appears to disproportionately affect people with pre-existing mental health problems or physical disabilities. As post-COVID-19 rehabilitation services are being developed, individualised pathways should be considered to accommodate the needs of these vulnerable populations.
Trial Registration ClinicalTrials.gov: NCT04354519
Competing Interest Statement
Afagh Garjani has received research support from the United Kingdom Multiple Sclerosis Society, speaker honorarium from the Multiple Sclerosis Academy, and travel support from Novartis. Rodden M Middleton has received funding from the United Kingdom Multiple Sclerosis Society. Richard Nicholas has received support for advisory boards and travel from Novartis, Roche, and Biogen. He has received grant support from the United Kingdom Multiple Sclerosis Society. He is a member of a National Institute for Health and Care Excellence (NICE) Health Technology Assessment (HTA) committee. Nikos Evangelou has served as a member of advisory boards for Biogen, Merck, Novartis, and Roche and has received grant income from the United Kingdom Multiple Sclerosis Society, Medical Research Council (MRC), Patient-Centered Outcomes Research Institute (PCORI), and National Institute for Health Research (NIHR).
Clinical Trial
ClinicalTrials.gov: NCT04354519
Funding Statement
The study was funded by the United Kingdom Multiple Sclerosis Society (131).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The United Kingdom Multiple Sclerosis Register studies have been approved by Southwest-Central Bristol Research Ethics Committee: 16/SW/0194
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are stored on the UKMSR Secure e-Research Platform at Swansea University Medical School. Line level data cannot be released, but qualified researchers, subject to governance, can request access to data.
